Call +44 (0)1904 798634 or +44 (0)7550 079918

Leading provider of life science market reports and research services

Dermatology Therapeutics Drug Development Pipeline Review, 2016

Be the first to review this product

Dermatology Therapeutics Drug Development Pipeline Review, 2016

Summary

Dermatological conditions are one of the most common types of disorders worldwide, and approximately one-third of the US...
You can choose to pay by purchase order during checkout

Availability: In stock

$3,995.00

* Required Fields

You can choose to pay by purchase order during checkout
GBI Research.

Digital downloads direct to your inbox within 24 hours.

First class customer service from our team of experts.

Pay by credit card or request an invoice

Product Description

Details

Dermatology Therapeutics Drug Development Pipeline Review, 2016

Summary

Dermatological conditions are one of the most common types of disorders worldwide, and approximately one-third of the US population suffers from at least one active skin condition. For the past decades, the majority of the dermatology market has remained saturated with established and generic products. However, the clinical and commercial success of biologics in the treatment of psoriasis, as well as advancements in the understanding of the disease pathways of many dermatological conditions, have led to a renewed interest from pharmaceutical companies in the dermatology market, and subsequently the emergence of an innovative pipeline.

There are over 800 products in active development in the dermatology therapy area, with the majority of products being small molecules. Biologics represent approximately 40% of the pipeline, despite the fact that this molecule type represents only a small fraction of the marketed products landscape.

Overall, the dermatology pipeline is highly innovative, owing to the advancements in the understanding of the disease pathways of many skin disorders. The number of strong late-stage products and substantial early-stage segment of this active and diverse pipeline are strong indicators of long-term growth in this market.

The report provides comprehensive information on the pipeline development landscape for is Acne vulgaris, Psoriasis and Atopic dermatitis, from Discovery through to the Pre-Registration stage. This includes an analysis of products by stage of development, molecular target, mechanism of action (MoA), route of administration (RoA) and molecule type. A list of all products in development is provided, including dormant and discontinued projects. Finally, the report provides an overview of key players involved in the development of products in this area, and outlines recent updates and press releases in the field.

Scope

- Which companies are the most active within the pipeline for dermatology?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Additional Information

Additional Information

Publisher name GBI Research.
Format PDF
Page count 432
Publication date 15 Dec 2016
Table of contents Table of Contents
GBI Research Report Guidance 2
Executive Summary 3
Table of Contents 4
List of Tables 6
List of Figures 13
Introduction 15
GBI Research Report Coverage 15
Acne Vulgaris Overview 15
Psoriasis Overview 15
Atopic Dermatitis Overview 15
Therapeutics Development 16
Acne Vulgaris 16
Psoriasis 18
Atopic Dermatitis 20
Therapeutics under Development by Companies 22
Acne Vulgaris 22
Psoriasis 24
Atopic Dermatitis 31
Therapeutics under Investigation by Universities/Institutes 34
Acne Vulgaris 34
Psoriasis 35
Atopic Dermatitis 36
Pipeline Products Glance 37
Acne Vulgaris 37
Psoriasis 40
Atopic Dermatitis 44
Products under Development by Companies 47
Acne Vulgaris 47
Psoriasis 49
Atopic Dermatitis 58
Products under Investigation by Universities/Institutes 62
Acne Vulgaris 62
Psoriasis 62
Atopic Dermatitis 63
Companies Involved in Therapeutics Development 64
Acne Vulgaris 64
Psoriasis 95
Atopic Dermatitis 245
Therapeutics Assessment 323
Acne Vulgaris 323
Psoriasis 335
Atopic Dermatitis 363
Dormant Projects 377
Acne Vulgaris 377
Psoriasis 380
Atopic Dermatitis 389
Discontinued Products 392
Acne Vulgaris 392
Psoriasis 392
Atopic Dermatitis 395
Product Development Milestones 396
Acne Vulgaris 396
Psoriasis 408
Atopic Dermatitis 420
Appendix 431
Methodology 431
Coverage 431
Secondary Research 431
Primary Research 431
Expert Panel Validation 431
Contact Us 431
Disclaimer 432

Reviews

Write Your Own Review

Only registered users can write reviews. Please, log in or register